Santen Pharmaceutical Co., Ltd.

Text Size
  • Small
  • Medium
  • Large

About Santen

Company History

  • 1890-1950
  • 1951-2000
  • 2001-Current


2001 Detantol
Detantol, a treatment for glaucoma and ocular hypertension, and Livostin, and anti-allergy ophthalmic solution, launched in Japan
Santen acquires the U.S. firm Advanced Vision Science, Inc.
Advanced Vision Science is a medical device company specializing in the research, development and manufacturing of ophthalmic medical devices. Its innovative development of intraocular lenses is expected to proffer a competitive advantage in the ophthalmology market.
2002 Dimple Bottle
Introduced the Dimple Bottle, newly developed for higher usability, distinguishability and productivity
2003-2005 Medium-term Management Plan (PDF: 142KB)PDF devised
Shanghai Representative Office established
Santen Pharmaceutical (China) Co., Ltd. established
PAPILOCK Mini ophthalmic solution 0.1%, a treatment for vernal keratoconjunctivitis, launched in Japan
2006-2010 Medium-term Management Plan (PDF: 535KB)PDF devised
2007 Suzhou Plant
Suzhou Plant established in China
Sante Medical 10 launched in Japan
2008 Eternity, Tapros / Taflotan
Sante Lutax, nutritional supplement launched in Japan
Santen 40i launched in Japan
Eternity foldable intraocular lens launched in Japan
Santen launches Tapros, a treatment for glaucoma and ocular hypertension
Tapros is the fruit of Santen's first global development project spanning Japan, the U.S., Europe and Asia. The product is currently being sold in Japan as well as countries in Europe and Asia, and is gaining attention in ophthalmic markets in Japan and around the world as a new type of drug that fulfills unmet needs in the glaucoma treatment domain.
Sante FX V Plus launched in Japan
Eternity Natural, a foldable intraocular lens, launched in Japan
2010 Diquas
Cosopt, a treatment of glaucoma and ocular hypertension, launched in Japan
Diquas, a treatment for dry eye syndrome, launched
Diquas is the world's first eye drop to take advantage of the pharmacological action of a P2Y2 receptor agonist. The drug treats dry eye by promoting the secretion of water and mucin, one of the major components of tears, and returning the tear film coating in the eye back to its normal state.
2011-2013 Medium-Term Management Plan (PDF: 297KB)PDF formulated
Santen India Private Limited established
Accuject injector launched for inserting intraocular lenses
2012 EYLEA
Santen acquires Novagali Pharma S.A.S. and makes it a wholly owned subsidiary
Santen Holdings EU B.V. established as a holding company
Sante Medical Guard launched
VEGF inhibitor EYLEA solution for intravitreal injection launched for the treatment of patients with wet age-related macular degeneration.
Pharmaceutical information is offered together with Bayer Yakuhin, Ltd.
Sante Beautéye launched in Japan
Sante PC launched in Japan
TAPROS MINI, a treatment of glaucoma and ocular hypertension, launched in Japan
Ho Chi Minh Representative Office established
Sante Kaiteki 40 launched in Japan
Alesion, a treatment of allergic conjunctivitis, launched in Japan
Santen Pharmaceutical Asia Pte.Ltd. established in Singapore
Sante ALn launched in Japan
  • 1951-2000